Comparison of Zai Lab Limited (ZLAB) and Ra Pharmaceuticals Inc. (NASDAQ:RARX)

Both Zai Lab Limited (NASDAQ:ZLAB) and Ra Pharmaceuticals Inc. (NASDAQ:RARX) are Biotechnology companies, competing one another. We will contrast their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zai Lab Limited N/A 0.00 67.46M -2.65 0.00
Ra Pharmaceuticals Inc. N/A 0.00 63.89M -2.27 0.00

Demonstrates Zai Lab Limited and Ra Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Zai Lab Limited 0.00% 0% 0%
Ra Pharmaceuticals Inc. 0.00% -72.3% -64.8%

Liquidity

The current Quick Ratio of Zai Lab Limited is 17.8 while its Current Ratio is 17.8. Meanwhile, Ra Pharmaceuticals Inc. has a Current Ratio of 10.3 while its Quick Ratio is 10.3. Zai Lab Limited is better positioned to pay off its short-term and long-term debts than Ra Pharmaceuticals Inc.

Insider & Institutional Ownership

Roughly 66.4% of Zai Lab Limited shares are held by institutional investors while 77% of Ra Pharmaceuticals Inc. are owned by institutional investors. About 35.54% of Zai Lab Limited’s share are held by insiders. Competitively, insiders own roughly 5.62% of Ra Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Zai Lab Limited 1.01% 8.85% 11.91% -16.51% -22.04% -6.17%
Ra Pharmaceuticals Inc. 11.73% 27.68% 40.85% 110.51% 129.73% 107.29%

For the past year Zai Lab Limited has -6.17% weaker performance while Ra Pharmaceuticals Inc. has 107.29% stronger performance.

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor for the treatment of ovarian, breast, and lung cancers; ZL-2401, an antibiotic for the treatment of acute bacterial skin/skin structure infections, community-acquired bacterial pneumonias, and urinary tract infections; ZL-2301 that is Phase II clinical trial for the treatment of hepatocellular carcinoma; ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; ZL-2302 for the treatment of non-small cell lung cancer; and ZL-1101, an anti-OX40 antagonistic antibody for the treatment of graft-versus-host disease or systemic lupus erythematosus. The company was founded in 2013 and is headquartered in Shanghai, China.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The companyÂ’s preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.